Clinical trials
Autoimmunity clinical trials
Below are recruiting autoimmunity clinical trials, each written for real people, not researchers. We’re tracking 348 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06279923RecruitingEarly Phase 1
CAR-T cells for autoimmune diseases
This trial tests a new CAR-T cell therapy that targets two immune proteins (CD19 and BAFF) to treat autoimmune diseases like lupus or scleroderma. It is for people who have not improved with standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06318533RecruitingEarly Phase 1
CAR NK cell therapy for tough autoimmune diseases
This study tests a new type of immune cell therapy (CAR NK cells) targeting B cells to treat autoimmune diseases that haven't responded to standard treatments. It's an early-phase trial to see if it's safe and helpful for people with moderate to severe disease.
Zhenjiang, JiangsuAges 18–70 - NCT06381453RecruitingPhase 2
Belimumab for autoimmune hepatitis
This trial tests a drug called belimumab for people with autoimmune hepatitis that is not well controlled. It aims to see if adding belimumab to your current treatment can help reduce liver inflammation.
Calgary, AlbertaAges 18–80 - NCT06387654Recruiting
Collection of skin samples for immune-related skin diseases
This study collects skin samples and medical information from people with skin conditions caused by their immune system. It helps researchers better understand these diseases and develop new treatments.
ToulouseAges 6–99 - NCT06428188RecruitingPhase 1/Phase 2
CAR-T cells targeting BCMA/CD19 for autoimmune diseases
This trial tests a new treatment called CAR-T cells that target two proteins (BCMA and CD19) on immune cells. It is for people with certain autoimmune diseases that have not improved with standard treatments.
Beijing, Beijing MunicipalityAges 21–90 - NCT06431776RecruitingPhase 3
Inhaled molgramostim for kids with autoimmune PAP
This study tests an inhaled medicine called molgramostim for children with autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung condition. The goal is to see if the drug can improve lung function and reduce the need for whole lung lavage (a washing procedure).
MünchenAges 6–18 - NCT06434363RecruitingPhase 1/Phase 2
Cell therapy plus tafasitamab for autoimmune diseases
This trial tests a new cell therapy (AD-PluReceptor) combined with the drug tafasitamab for people with certain autoimmune diseases like systemic sclerosis, lupus, or chronic graft-versus-host disease. It aims to see if this treatment can help when standard therapies have failed.
Houston, TexasAges 18 years+ - NCT06435468Recruiting
Biocollection for rare childhood-onset immune diseases
This study collects blood and tissue samples from patients with rare immune system diseases that started in childhood, and from their relatives and healthy volunteers. The goal is to build a biocollection for future research to better understand these diseases.
Bron, BronAges 1 year+ - NCT06435897RecruitingPhase 1/Phase 2
MSC and CAR-T cell therapy for autoimmune disease
This trial tests a new treatment using a combination of two types of immune cells (MSCs and CAR-T cells) to calm the immune system and treat autoimmune diseases. It may help people whose autoimmune condition is not well controlled with current medications.
Shenzhen, GuangdongAges 18–75 - NCT06455280RecruitingPhase 1
A study of Siplizumab for autoimmune liver disease patients awaiting transplant
This trial tests a drug called Siplizumab in people with autoimmune hepatitis or primary sclerosing cholangitis who are on the liver transplant waitlist. It aims to see if the drug can help manage their condition before and after transplant.
New York, New YorkAges 18 years+ - NCT06464679RecruitingPhase 1
CD19 CAR NK cells for autoimmune diseases
This trial tests a new type of immune cell therapy (CD19 CAR NK cells) for people with certain autoimmune diseases that have not responded to standard treatments. The goal is to see if these cells can safely reduce disease activity.
ShanghaiAges 18–65 - NCT06503224Recruiting
Cell therapy for refractory autoimmune diseases
This trial tests a new type of cell therapy (SCAR02) that targets two proteins on immune cells to help calm down overactive autoimmune diseases like rheumatoid arthritis, lupus, Sjögren's syndrome, or systemic sclerosis. It may be an option if standard treatments haven't worked well enough.
Changsha, HunanAges 18 years+ - NCT06548607RecruitingEarly Phase 1
CAR-T therapy for autoimmune diseases
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
Bengbu, AnhuiAges 18–70 - NCT06584045Recruiting
Testing a bile-based treatment for adult encephalitis
This study tests a natural bile-derived medicine (Calcus Bovis Sativus) to see if it can help adults with new or recent brain inflammation (encephalitis). It focuses on people whose encephalitis is caused by the immune system or a virus, and who have not fully recovered.
Wuhan, HubeiAges 18 years+ - NCT06587828Recruiting
Looking at immune cells in people with autoimmune disease
This study collects blood, tissue, and other samples from people with autoimmune diseases like Crohn's disease, multiple sclerosis, or lupus. Researchers will study your immune cells (T cells) to learn what they are attacking, which could lead to better treatments in the future.
Orange, CaliforniaAges 18 years+ - NCT06680037RecruitingPhase 1
Azer-cel for autoimmune disorders like MS, NMOSD, MG, and CIDP
This trial tests an investigational cell therapy called Azer-cel in people with certain autoimmune diseases that affect the nerves or muscles. It aims to see if the treatment is safe and can help reduce symptoms by targeting the immune system.
La Jolla, CaliforniaAges 18 years+ - NCT06680388RecruitingEarly Phase 1
CD19 CAR-T for severe autoimmune diseases
This trial tests whether a special immune cell treatment (CD19 CAR-T) can help people with certain severe autoimmune diseases that have not improved with standard therapies. It is a very early study to see if the treatment is safe and effective for conditions like lupus, systemic sclerosis, vasculitis, myositis, or Sjögren's syndrome.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06688799RecruitingPhase 1/Phase 2
Anti-CD19 CAR T cells for refractory autoimmune diseases
This trial tests a special immune cell therapy (CAR T cells) for people with severe lupus, Sjogren's syndrome, systemic sclerosis, and other autoimmune conditions that haven't improved with standard treatments. The therapy is designed to target and reset the immune system.
Beijing, Beijing MunicipalityAges 3–65 - NCT06730126RecruitingPhase 2
Soquelitinib for ALPS-FAS-related swelling and low blood counts
This trial tests an investigational drug called soquelitinib to see if it can shrink enlarged lymph nodes and improve low blood cell counts in people with ALPS-FAS. It may offer a new treatment option for those who have active symptoms.
Bethesda, MarylandAges 16–120 - NCT06747156RecruitingEarly Phase 1
mRNA medicine for refractory autoimmune diseases
This trial tests a new type of medicine (ABO2203) that trains your immune system to attack the cells causing your autoimmune disease. It's for people who haven't gotten better with standard treatments.
Wuhan, HubeiAges 18 years+ - NCT06767605Recruiting
Spanish registry for autoimmune liver diseases
This study collects information from people with autoimmune or cholestatic liver diseases to better understand them and improve care. It does not test a new treatment, but your participation can help future research.
BarcelonaAges 18 years+ - NCT06792799RecruitingEarly Phase 1
CAR-NK cells for B-cell autoimmune diseases
This early phase trial tests a new treatment made from immune cells (CAR-NK cells) that target and destroy overactive B cells. It may help people with lupus, certain kidney diseases, or nephrotic syndrome that hasn't responded to standard therapies.
Hangzhou, ZhejiangAges 3 years+ - NCT06881511Recruiting
Betaine for autoimmune gastritis
This study tests whether betaine hydrochloride, a supplement that helps with digestion, can improve symptoms in people with autoimmune gastritis. It is for adults who have been diagnosed with this condition and have high gastrin levels or a related stomach history.
Hangzhou, ZhejiangAges 18–80 - NCT06888960RecruitingEarly Phase 1
Testing CC312 for people with autoimmune diseases
This early-phase study tests a new drug called CC312 in patients with certain autoimmune diseases like lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia. The goal is to see if it's safe and how the body handles it.
Tianjin, ChinaAges 18 years+
Hear when a new Autoimmunity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for autoimmunity?
- Yes. Clin2 currently lists 348 recruiting autoimmunity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a autoimmunity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a autoimmunity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.